Patent Assignment Details
NOTE:Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.
|
Reel/Frame: | 059356/0815 | |
| Pages: | 34 |
| | Recorded: | 03/09/2022 | | |
Attorney Dkt #: | UEONK1-0000LS |
Conveyance: | ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). |
|
Total properties:
7
|
|
Patent #:
|
|
Issue Dt:
|
09/23/2014
|
Application #:
|
13538778
|
Filing Dt:
|
06/29/2012
|
Publication #:
|
|
Pub Dt:
|
01/24/2013
| | | | |
Title:
|
ANTIBODIES THAT SPECIFICALLY BIND TO TIM3
|
|
|
Patent #:
|
|
Issue Dt:
|
10/20/2015
|
Application #:
|
13794525
|
Filing Dt:
|
03/11/2013
|
Publication #:
|
|
Pub Dt:
|
11/07/2013
| | | | |
Title:
|
ANTIBODIES SPECIFIC FOR CLL-1
|
|
|
Patent #:
|
|
Issue Dt:
|
04/25/2017
|
Application #:
|
14458053
|
Filing Dt:
|
08/12/2014
|
Publication #:
|
|
Pub Dt:
|
03/26/2015
| | | | |
Title:
|
ANTIBODIES THAT SPECIFICALLY BIND TO TIM3
|
|
|
Patent #:
|
|
Issue Dt:
|
12/26/2017
|
Application #:
|
14853881
|
Filing Dt:
|
09/14/2015
|
Publication #:
|
|
Pub Dt:
|
12/31/2015
| | | | |
Title:
|
ANTIBODIES SPECIFIC FOR CLL-1
|
|
|
Patent #:
|
|
Issue Dt:
|
05/28/2019
|
Application #:
|
15462538
|
Filing Dt:
|
03/17/2017
|
Publication #:
|
|
Pub Dt:
|
11/02/2017
| | | | |
Title:
|
ANTIBODIES THAT SPECIFICALLY BIND TO TIM3
|
|
|
Patent #:
|
|
Issue Dt:
|
07/27/2021
|
Application #:
|
15779025
|
Filing Dt:
|
05/24/2018
|
Publication #:
|
|
Pub Dt:
|
12/13/2018
| | | | |
Title:
|
HUMANIZED ANTI-CLL-1 ANTIBODIES
|
|
|
Patent #:
|
|
Issue Dt:
|
07/28/2020
|
Application #:
|
15853056
|
Filing Dt:
|
12/22/2017
|
Publication #:
|
|
Pub Dt:
|
09/27/2018
| | | | |
Title:
|
ANTIBODIES SPECIFIC FOR CLL-1
|
|
Assignee
|
|
|
PIER ROAD |
UNIT 1 AN COIRNEAL |
BARNA, IRELAND H91 V6KV |
|
Correspondence name and address
|
|
DEAN G. STATHAKIS
|
|
2372 MORSE AVENUE, SUITE 252
|
|
IRVINE, CA 92612
|
Search Results as of:
05/25/2024 10:20 PM
If you have any comments or questions concerning the data displayed,
contact
PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified:
August 25, 2017 v.2.6
|